Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients? - PubMed
. 2015 Jul;54(7):1257-61.
doi: 10.1093/rheumatology/keu459. Epub 2015 Jan 12.
Affiliations
- PMID: 25587178
- DOI: 10.1093/rheumatology/keu459
Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?
Lodewijk de Groot et al. Rheumatology (Oxford). 2015 Jul.
Abstract
Objective: The incidence of cardiovascular disease (CVD) is increased in RA. This study was designed to evaluate whether a reduction in disease activity influences early markers of CVD.
Methods: In a prospective longitudinal study, 58 newly diagnosed RA patients and 58 age- and sex-matched healthy controls (HCs) were included. Endothelial dysfunction was measured by small artery elasticity (SAE) and endothelial cell activation was assessed by measuring soluble vascular cellular activation molecule 1(sVCAM-1) and von Willebrand factor (vWF). Advanced glycation end products (AGEs) were quantified by skin autofluorescence. After 1 year, measurements were repeated in all RA patients.
Results: At entry, SAE was decreased in RA vs HCs [median 3.4 ml/mmHg100 (range 1.2-9.0) vs 6.1 (range 5.0-15.3), P < 0.0001] and sVCAM-1 and vWF were increased: 391 ng/ml (range 256-680) vs 341 (range 223-691) (P = 0.0015) and 120 ng/ml (range 26.5-342) vs 99 (range 22-298) (P = 0.02), respectively. SAE was inversely correlated with the 28-joint DAS (DAS28; r = -0.31, P = 0.016). AGEs were increased by 2.55 arbitrary units (range 1.29-4.65) vs 2.12 (range 1.32-3.82) in HCs (P = 0.003). In multivariate analysis, the presence of RA, age and systolic blood pressure were independently and inversely related to SAE. After 1 year, SAE had significantly improved in RA, from 3.4 (range 1.2-9.0) to 3.8 (range 1.5-10.3) (P = 0.03).
Conclusion: Endothelial dysfunction is present in newly diagnosed RA patients, independently of traditional risk factors and is inversely correlated with disease activity. By reducing disease activity, endothelial dysfunction improves, although not to normal values. Also, a reduction in disease activity targeting traditional risk factors remains important in preventing CVD in RA.
Keywords: advanced glycation end products; atherosclerosis; endothelial cell activation; endothelial dysfunction; intima-media thickness; rheumatoid arthritis; small artery elasticity.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Similar articles
-
de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CG, Bijl M, Posthumus MD. de Groot L, et al. Arthritis Res Ther. 2011;13(6):R205. doi: 10.1186/ar3538. Epub 2011 Dec 14. Arthritis Res Ther. 2011. PMID: 22168993 Free PMC article.
-
Hinkema HJ, Nienhuis HL, de Groot L, Smit AJ, van Roon AM, Bijl M, Posthumus MD. Hinkema HJ, et al. J Rheumatol. 2011 Oct;38(10):2133-40. doi: 10.3899/jrheum.100989. Epub 2011 Aug 15. J Rheumatol. 2011. PMID: 21844153
-
Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis.
Syngle A, Vohra K, Garg N, Kaur L, Chand P. Syngle A, et al. Int J Rheum Dis. 2012 Feb;15(1):45-55. doi: 10.1111/j.1756-185X.2011.01679.x. Epub 2011 Oct 10. Int J Rheum Dis. 2012. PMID: 22324946
-
[Assessment of endothelial function in autoimmune diseases].
Benhamou Y, Bellien J, Armengol G, Gomez E, Richard V, Lévesque H, Joannidès R. Benhamou Y, et al. Rev Med Interne. 2014 Aug;35(8):512-23. doi: 10.1016/j.revmed.2013.12.010. Epub 2014 Jan 10. Rev Med Interne. 2014. PMID: 24412013 Review. French.
-
Microvascular endothelial dysfunction in rheumatoid arthritis.
Bordy R, Totoson P, Prati C, Marie C, Wendling D, Demougeot C. Bordy R, et al. Nat Rev Rheumatol. 2018 Jul;14(7):404-420. doi: 10.1038/s41584-018-0022-8. Nat Rev Rheumatol. 2018. PMID: 29855620 Review.
Cited by
-
Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions.
Hong J, Maron DJ, Shirai T, Weyand CM. Hong J, et al. Int J Clin Rheumtol. 2015 Oct;10(5):365-381. doi: 10.2217/ijr.15.33. Int J Clin Rheumtol. 2015. PMID: 27042216 Free PMC article.
-
Saz-Lara A, Álvarez-Bueno C, Martínez-Vizcaíno V, Notario-Pacheco B, Sequí-Dominguez I, Cavero-Redondo I. Saz-Lara A, et al. Int J Environ Res Public Health. 2020 Sep 22;17(18):6936. doi: 10.3390/ijerph17186936. Int J Environ Res Public Health. 2020. PMID: 32972023 Free PMC article.
-
Verhoeven F, Totoson P, Maguin-Gaté K, Prigent-Tessier A, Marie C, Wendling D, Moretto J, Prati C, Demougeot C. Verhoeven F, et al. Clin Exp Immunol. 2017 May;188(2):208-218. doi: 10.1111/cei.12938. Epub 2017 Mar 9. Clin Exp Immunol. 2017. PMID: 28152574 Free PMC article.
-
Hloch K, Doseděl M, Duintjer Tebbens J, Žaloudková L, Medková H, Vlček J, Soukup T, Pávek P. Hloch K, et al. Front Pharmacol. 2021 Nov 5;12:703279. doi: 10.3389/fphar.2021.703279. eCollection 2021. Front Pharmacol. 2021. PMID: 34803668 Free PMC article.
-
Totoson P, Maguin-Gaté K, Nappey M, Wendling D, Demougeot C. Totoson P, et al. PLoS One. 2016 Jan 13;11(1):e0146744. doi: 10.1371/journal.pone.0146744. eCollection 2016. PLoS One. 2016. PMID: 26761790 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous